Carlsmed (CARL) Liabilities and Shareholders Equity (2024 - 2026)

Carlsmed (CARL) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $118.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 121.89% year-over-year to $118.2 million; the trailing twelve-month figure through Jun 2026 stood at $502.0 million (up 377.62% YoY), and the FY2025 full-year result was $130.1 million, up 151.08% from the prior year.
• Liabilities and Shareholders Equity was little changed at $118.2 million in Q2 2026 per CARL's latest filing, from $118.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $134.9 million in Q3 2025 and bottomed at $51.8 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $101.2 million across 3 years, with a median of $118.5 million in 2026.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity surged 151.08% in 2025, then surged 121.89% in 2026.
• Over 3 years, Liabilities and Shareholders Equity stood at $51.8 million in 2024, then jumped by 151.08% to $130.1 million in 2025, then retreated by 9.16% to $118.2 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $118.2 million, $118.8 million, and $130.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.